Pipeline: Adjuvant Therapy Against Sporadic Parkinson's Disease with a small molecule (BLT 002)

Biolink Therapeutics is a biotech startup driven by a passionate team of seasoned scientists from the US, Europe, and India, united in the fight against human diseases including neurodegenerative diseases. With a sharp focus on sporadic Parkinson’s disease—the most prevalent and challenging form—we are pioneering a novel adjuvant therapy built with a patented molecule (confidential, under licensing process). This innovative approach is designed to slow disease progression and enhance the effectiveness of current treatments. It may offer new hope to millions affected by Parkinson’s. At Biolink, we are not just developing therapies—we’re building a global bridge of translational science dedicated to transforming patient care.